Emergency & Toxicology

Lithium toxicity: acute and chronic

Clinical Overview and When to Suspect Lithium Toxicity

— Therapeutic serum level: 0.6–1.2 mEq/L (maintenance); acute mania up to 1.5 mEq/L

— Toxicity typically begins >1.5 mEq/L, severe >2.5 mEq/L, life-threatening >3.5 mEq/L — but chronic toxicity can be severe at "therapeutic" levels

— Acute: overdose in a lithium-naïve patient → high GI symptoms, relatively spared neuro early, level high but tissue burden low

— Acute-on-chronic: chronic user takes extra → mixed GI + neuro, worst prognosis

— Chronic: gradual accumulation from dehydration, NSAIDs, ACEi/ARBs, thiazides, low salt diet, new CKD, or febrile illness → predominantly neurologic at modest serum levels

— New tremor (coarse, not the fine baseline tremor), ataxia, dysarthria, confusion, myoclonus

— GI symptoms (N/V/diarrhea) after dose escalation

— Polyuria/polydipsia (nephrogenic DI) with subsequent dehydration spiraling into toxicity

— Recent start of HCTZ, lisinopril, ibuprofen, or celecoxib

— Acute illness with volume loss in a chronic user

— Renally excreted unchanged; ~95% reabsorbed at proximal tubule with Na⁺

— Volume contraction → ↑Na reabsorption → ↑Li reabsorption → toxicity

— Volume of distribution ~0.7 L/kg; distributes slowly into CNS, which is why CNS symptoms lag serum levels and persist after levels normalize

Board pearl: A patient with bipolar disorder on stable lithium who develops gastroenteritis, starts an ACE inhibitor for new hypertension, or begins ibuprofen for back pain is the classic chronic toxicity vignette — neuro findings dominate, level may be only 1.6–2.0, but the patient is sicker than the number suggests.

Lithium is a narrow therapeutic index mood stabilizer used in bipolar disorder, schizoaffective disorder, and as augmentation in unipolar depression

Three toxicity patterns the boards love:

Suspect lithium toxicity in any bipolar patient with:

Pharmacokinetic pearls:

Presentation Patterns and Key History

— Onset within 1–4 hours; sustained-release preparations delay peak to 6–12 hours

— Early: nausea, vomiting, watery diarrhea, abdominal pain dominate

— Neuro symptoms appear hours-to-days later as lithium distributes into CNS

— Serum level may be strikingly high (>4 mEq/L) with deceptively mild symptoms initially

— Insidious over days to weeks

— Neurologic predominance: coarse tremor, hyperreflexia, clonus, fasciculations, ataxia, dysarthria, nystagmus, confusion, lethargy → seizures, coma

— GI symptoms mild or absent

— SILENT syndrome (Syndrome of Irreversible Lithium-Effectuated NeuroToxicity): persistent cerebellar dysfunction, cognitive impairment, extrapyramidal symptoms after toxicity resolves

— Indication and duration of lithium use, last dose, formulation (IR vs ER)

— Recent dose changes

— New medications: thiazides, ACEi/ARBs, NSAIDs, metronidazole, tetracyclines, SSRIs

— Recent illness with fever, vomiting, diarrhea, poor PO intake

— Low-salt diet or new diuretic use

— Polyuria, polydipsia, weight changes (suggesting nephrogenic DI)

— Suicidal intent (alters disposition and psychiatric hold considerations)

— Grade 1: tremor, hyperreflexia, agitation, weakness

— Grade 2: stupor, rigidity, hypertonia, hypotension

— Grade 3: coma, seizures, myoclonus, cardiovascular collapse

Key distinction: In acute toxicity, GI symptoms precede neuro by hours; in chronic toxicity, neuro symptoms dominate and GI is minimal. Confusing the two leads to underestimating severity in chronic users with "only" a 2.0 level.

Acute ingestion (lithium-naïve or massive overdose):

Chronic toxicity:

Acute-on-chronic: worst of both worlds; high tissue burden + new bolus

Key history questions on the CCS-style stem:

Severity grading (clinical, Hansen-Amdisen):

Physical Exam Findings and Hemodynamic Assessment

— Hypotension in severe toxicity from volume depletion, vasodilation, and cardiac depression

— Bradycardia or sinus node dysfunction possible

— Hyperthermia in severe cases (and overlap with serotonin syndrome/NMS when on coadministered agents)

— Tachypnea from metabolic acidosis or aspiration

— Coarse tremor of outstretched hands (fine tremor is baseline therapeutic effect)

— Hyperreflexia, clonus, myoclonus, fasciculations

— Cerebellar signs: ataxia, dysmetria, dysdiadochokinesia, nystagmus, scanning dysarthria

— Altered mental status ranging from mild confusion to coma

— Seizures (often generalized tonic-clonic) in severe cases

— Choreoathetosis, cogwheel rigidity, extrapyramidal signs

— Dry mucous membranes, poor skin turgor, flat JVP, orthostatics

— Nephrogenic DI patients often profoundly volume-depleted despite drinking

— Urine output: polyuria (DI) vs oliguria (AKI from volume depletion)

— ECG: T-wave flattening/inversion, U waves, QT prolongation, sinus bradycardia, SA block

— Rarely Brugada-like pattern unmasked

— Goiter or hypothyroid features (chronic lithium → hypothyroidism in ~20%)

— Tongue lateral biting marks (recent seizure)

— Track marks or pill bottles at scene (acute ingestion)

Step 3 management: First exam priorities — airway protection (GCS <8 → intubate), IV access ×2, fingerstick glucose, ECG, and immediate volume status assessment. Start isotonic saline at 150–200 mL/h in any volume-depleted lithium toxicity patient pending labs; this both treats AKI and enhances lithium clearance.

Vital signs:

Neurologic exam (the money exam in lithium toxicity):

Volume status assessment — critical because it drives management:

Cardiovascular:

Other system clues:

Diagnostic Workup — Initial Labs, Imaging, ECG

— Draw immediately, repeat every 2–4 hours until peaking and trending down

— Sustained-release ingestions can peak at 6–12+ hours

— Use plain (not lithium-heparin) tube — lithium-heparin tubes falsely elevate

— Level does NOT correlate well with symptoms in chronic toxicity

— BUN/creatinine: AKI is common and worsens toxicity (vicious cycle)

— Sodium: hypernatremia suggests nephrogenic DI; hyponatremia worsens lithium reabsorption

— Potassium, bicarbonate (metabolic acidosis in severe cases)

— Calcium: chronic lithium can cause hypercalcemia from lithium-induced hyperparathyroidism

— Low urine osm with serum hypernatremia → nephrogenic DI

— Urine specific gravity often inappropriately low (<1.010)

— T-wave flattening/inversion most common

— QT prolongation, sinus bradycardia, SA exit block, AV blocks

— Compare to prior ECG when available

Board pearl: A lithium level drawn in a lithium-heparin tube can read falsely high by 1–2 mEq/L. If a level seems incongruent with clinical picture (level 4.2 but patient looks well), redraw in a plain or EDTA tube before pulling the dialysis trigger.

Serum lithium level — cornerstone but interpret with context:

Basic metabolic panel:

TSH and free T4: chronic lithium → hypothyroidism (and rarely hyperthyroidism); useful baseline if not recent

CBC: lithium causes benign leukocytosis (~12–15K) — don't anchor on infection

Urinalysis and urine osmolality:

ECG (mandatory):

Pregnancy test in reproductive-age women (changes management and disposition)

Acetaminophen and salicylate levels in any intentional ingestion — co-ingestion screening

Coingestant tox screen including ethanol

CT head if focal deficits, persistent altered mental status, or trauma suspected — rule out alternative cause

Diagnostic Workup — Advanced or Confirmatory Studies

— Every 2–4 hours until clearly trending downward and below 1.5 mEq/L

— Watch for rebound rise after hemodialysis as lithium redistributes from tissues to plasma — recheck 6–8 hours post-HD

— Sustained-release (Eskalith CR, lithobid) ingestions may show late peaks at 12–24 hours

— Calculate creatinine clearance; eGFR drives clearance and dialysis decisions

— Urine output goal 1–2 mL/kg/h with IVF resuscitation

— Anion gap metabolic acidosis suggests severe toxicity, seizure activity, or coingestion

— Respiratory status in altered patients

— Abdominal X-ray: lithium tablets, especially sustained-release, may be radiopaque — can confirm ongoing GI burden and guide whole-bowel irrigation

— MRI brain: not routine acutely; consider for persistent neurologic deficits after toxicity resolves (SILENT syndrome workup)

— If on SSRIs/SNRIs with hyperthermia, hyperreflexia, clonus → consider concurrent serotonin syndrome

— If on antipsychotics with rigidity, hyperthermia → consider concurrent NMS

CCS pearl: In severe acute ingestion, order lithium level q2h, BMP q4h, ECG on admission then q12h, continuous cardiac monitoring, and reassess clinical exam every 2 hours. Document a clear trajectory before stopping fluids or stepping down monitoring.

Serial lithium levels are the most important confirmatory study:

Renal function trending:

Arterial or venous blood gas:

Magnesium and phosphate: often deranged with diuretic-driven chronic toxicity; replete aggressively

Lactate: elevated in shock, seizures, or mesenteric hypoperfusion

CK: rhabdomyolysis from seizures, immobility, hyperthermia

EEG if subclinical seizures suspected in obtunded patient — lithium toxicity can cause nonconvulsive status

Imaging considerations:

Echocardiogram: only if hemodynamic instability persists after volume resuscitation, or to evaluate for alternative causes of shock

Coingestion considerations:

Risk Stratification and First-Line Management Logic

— Asymptomatic + level <1.5: observe, recheck level, identify precipitant

— Mild symptoms (tremor, GI) + level 1.5–2.5: admit telemetry, IVF, serial levels

— Moderate (confusion, ataxia, hyperreflexia) + level 2.5–3.5: ICU, aggressive IVF, prepare for hemodialysis

— Severe (seizures, coma, hemodynamic instability) or level >4.0 acute / >2.5 chronic: emergent hemodialysis

— Level >4.0 mEq/L with impaired renal function, OR

— Level >5.0 mEq/L regardless, OR

— Decreased consciousness, seizures, or life-threatening dysrhythmia, OR

— Expected time to level <1.0 mEq/L with conventional management >36 hours

— Activated charcoal does NOT bind lithium — useless unless coingestion suspected

— Whole-bowel irrigation with polyethylene glycol (1–2 L/h) for sustained-release ingestions if within first few hours and airway protected

— Gastric lavage rarely indicated; consider for massive ingestion <1 hour

— No role for ipecac

— 0.9% normal saline is first-line — restores volume, corrects AKI, enhances renal lithium clearance

— Avoid hypotonic fluids (worsen Na-driven lithium reabsorption)

— Watch for fluid overload in CKD/CHF — these patients often need earlier HD instead

— Hold lithium

— Stop NSAIDs, ACEi/ARBs, thiazides

— Reassess all nephrotoxic and lithium-interacting drugs

Step 3 management: The classic exam trap is the chronic toxicity patient with level 2.8 who looks neurologically devastated — don't wait for level >4.0 to dialyze. Clinical severity drives the decision in chronic toxicity, not the absolute number.

Triage decision framework based on three axes — level, symptoms, kinetics:

EXTRIP (Extracorporeal Treatments in Poisoning) indications for HD:

Decontamination decisions:

Volume resuscitation:

Stop the offending agent:

Pharmacotherapy and Adjunctive Treatment

— 0.9% NaCl at 150–300 mL/h initially; titrate to urine output 1–2 mL/kg/h

— Continue until level <1.5 and clinically improved

— Monitor sodium, potassium, magnesium q4–6h

— Avoid forced diuresis with loop diuretics — causes volume depletion that worsens lithium reabsorption (older textbook recommendation now refuted)

— Seizures: lorazepam 2–4 mg IV first-line, repeat as needed; second-line levetiracetam or phenobarbital. Avoid phenytoin (less effective, may worsen toxicity)

— Agitation: low-dose benzodiazepines; avoid antipsychotics if NMS overlap suspected

— Nausea/vomiting: ondansetron (caution with QT); metoclopramide can lower seizure threshold

— Hyperthermia: cooling measures, fluids; avoid dantrolene unless NMS confirmed

— Hypotension: crystalloid first, then norepinephrine if persistent

— Stop lithium

— Amiloride 5–10 mg PO daily blocks ENaC, reduces lithium entry into collecting duct cells, improves polyuria

— Adequate free water replacement

— Low-solute diet; thiazides are paradoxically used only after toxicity resolves and under specialist care — never acutely

Board pearl: Activated charcoal binds lithium poorly and is not indicated. However, sodium polystyrene sulfonate (Kayexalate) does bind lithium and has shown some lithium-clearing benefit in trials — but causes hypokalemia and is not standard of care. Don't choose it on the exam unless explicitly framed.

There is no specific antidote for lithium — management is supportive and clearance-focused

IV fluids — the pharmacologic cornerstone:

Sodium bicarbonate: no proven benefit; not recommended routinely

Symptom-directed pharmacotherapy:

Bradyarrhythmias: atropine, transcutaneous pacing; transvenous pacing rarely needed

Manage nephrogenic DI if present:

Hold all interacting agents: NSAIDs, ACEi, ARBs, thiazides, metronidazole, tetracyclines, calcium channel blockers (verapamil/diltiazem can worsen neurotoxicity)

Hemodialysis and Extracorporeal Management

— Severe neurologic features (seizures, coma, life-threatening dysrhythmia) regardless of level

— Serum lithium >4.0 mEq/L with renal impairment

— Serum lithium >5.0 mEq/L in any patient

— Expected time to reach level <1.0 mEq/L > 36 hours with optimal supportive care

— Hemodynamic instability, inability to tolerate volume resuscitation (CHF, ESRD)

— Intermittent hemodialysis (IHD) is first-line — fastest clearance, 4–6 hour session

— Continuous renal replacement therapy (CRRT) considered for hemodynamically unstable patients who can't tolerate IHD, or as adjunct after IHD to prevent rebound

— Hybrid approach: IHD followed by CRRT often used in severe cases to mitigate rebound

— Serum lithium <1.0 mEq/L AND clinically improved

— Recheck level 6–8 hours after HD — rebound rise from tissue redistribution is expected and may require a second session

— Place temporary dialysis catheter (vascath) in IJ or femoral vein

— Nephrology consult early — don't wait for level results if patient is critically ill

— Concurrent ICU admission

— Hypotension during session (especially in volume-depleted patient — give albumin or saline)

— Bleeding from anticoagulation (use citrate or no-heparin protocols if bleeding risk)

— Catheter-related infections, pneumothorax

— Disequilibrium syndrome (rare, brief sessions)

CCS pearl: Order on arrival in severe toxicity: "Nephrology consult — urgent hemodialysis" alongside ICU admission, intubation if GCS <8, NS at 200 mL/h, lithium level q2h, continuous telemetry. Don't delay HD waiting for fluids to "work" in severe cases.

Hemodialysis is the definitive treatment for severe lithium toxicity — lithium is small (MW 7), uncharged, not protein-bound, low Vd → highly dialyzable

Indications (EXTRIP 2015 consensus):

Modality:

Endpoints for stopping HD:

Procedural considerations:

Complications of HD:

Pitfall: Single HD session may inadequately clear tissue stores → plan for repeat dialysis if level rebounds >1.0 or symptoms persist

Special Populations — Elderly and Renal/Hepatic Impairment

— Age-related decline in GFR lowers lithium clearance; therapeutic dose for a 30-year-old may be toxic for an 80-year-old

— Lower volume of distribution (less lean mass) → higher peak levels

— Increased CNS sensitivity — toxicity at "therapeutic" levels (0.8–1.0 mEq/L)

— Polypharmacy with ACEi, ARBs, thiazides, NSAIDs is endemic in this age group

— Concurrent dementia or Parkinson's masks early neurologic toxicity

— Lithium accumulates rapidly with any further GFR drop

— eGFR <30: lithium is generally contraindicated; consider valproate or lamotrigine

— eGFR 30–60: use cautiously, half-dose, level every 1–2 weeks initially, then monthly

— Acute illness or dehydration in CKD → rapid spiral into toxicity

— Lithium can be used but dosed only post-dialysis (single dose 3×/week)

— Trough levels just before next HD session

— Requires careful psychiatry-nephrology coordination

— Lithium is renally cleared, so liver disease does not directly affect clearance

— BUT cirrhotics on diuretics, with ascites and prerenal physiology, are at high risk of chronic toxicity

— Hepatorenal syndrome rapidly precipitates toxicity

— Often on ACEi/ARB, loop or thiazide diuretic, and salt restriction — all increase lithium levels

— Cardiorenal syndrome with worsening CKD compounds risk

— Consider lower target levels and more frequent monitoring

Step 3 management: An elderly patient on chronic lithium presenting with new tremor, ataxia, or confusion after starting hydrochlorothiazide or lisinopril should be evaluated for lithium toxicity even with a "normal" level. Stop the new med, hold lithium, hydrate, and recheck level in 12 hours.

Elderly patients are dramatically more vulnerable:

Recommended elderly target level: 0.4–0.8 mEq/L for maintenance

CKD patients:

Dialysis-dependent ESRD patients:

Hepatic impairment:

Heart failure:

Special Populations — Pregnancy, Pediatrics, Breastfeeding

— Lithium is Category D — crosses placenta freely

— First-trimester exposure: small absolute risk of Ebstein anomaly (~1/1000 vs 1/20,000 baseline) — risk previously overstated

— Risk-benefit favors continuation in moderate-to-severe bipolar disorder where relapse risk is high (postpartum psychosis, suicide)

— Fetal echocardiogram at 16–20 weeks if first-trimester exposure

— Pharmacokinetics change: GFR ↑ 50% in pregnancy → lithium levels drop → may need dose increase

— Peripartum (last weeks of pregnancy): GFR falls back, blood volume contracts → rapid rise in lithium levels; reduce dose by 25–50% near delivery

— Neonatal effects: floppy baby syndrome, hypotonia, cyanosis, neonatal nephrogenic DI, hypothyroidism, transient

— Lithium is excreted in breast milk; traditionally discouraged but recent data suggest cautious breastfeeding may be acceptable with monitoring of infant levels, TSH, BUN/Cr

— Decision individualized; coordinate with pediatrics and psychiatry

— Less common but seen in adolescents on lithium for bipolar disorder or in accidental ingestions

— Same general management; weight-based fluid resuscitation

— HD thresholds same; pediatric nephrology early consult

— Always screen for intentional self-harm in adolescents — psychiatric evaluation before discharge

— High relapse risk for bipolar disorder postpartum; restarting lithium often appropriate

— Sleep deprivation, dehydration, breastfeeding fluid losses → toxicity risk

— Close postpartum level monitoring (weekly × 4–6 weeks then monthly)

Board pearl: A pregnant woman with bipolar disorder on lithium near term who develops nausea, vomiting, and tremor — think toxicity from falling pregnancy GFR. Check level, reduce dose, hydrate. Don't simply attribute symptoms to pregnancy or labor prodrome.

Pregnancy:

Breastfeeding:

Pediatric lithium toxicity:

Postpartum considerations:

Complications and Adverse Outcomes

— Persistent neurologic dysfunction >2 months after lithium toxicity resolves

— Features: cerebellar ataxia, dementia, extrapyramidal symptoms, brainstem dysfunction

— Higher risk with prolonged toxicity, high peak levels, age, fever, concurrent antipsychotic use

— Often irreversible — prevention via prompt HD is critical

— Nephrogenic diabetes insipidus: 20–40% of chronic users; reduces collecting duct AQP2 expression

— Chronic interstitial nephritis with progressive CKD after years of use

— Acute kidney injury during toxicity events (often reversible)

— Rarely distal RTA, minimal change disease

— Hypothyroidism (~20% of chronic users) — check TSH every 6–12 months

— Hyperparathyroidism with hypercalcemia (~10%)

— Rarely hyperthyroidism (silent thyroiditis)

— Sinus node dysfunction (sick sinus)

— T-wave abnormalities (usually benign)

— Brugada-like ECG patterns can be unmasked

— Acute pure ingestion: low (<1%)

— Acute-on-chronic: highest mortality

— Chronic: morbidity dominated by SILENT syndrome and CKD

Key distinction: Lithium-induced nephrogenic DI persists even after stopping the drug in some patients; amiloride is the treatment of choice as it blocks ENaC and reduces lithium entry into collecting duct principal cells. Thiazides paradoxically work but raise lithium levels — avoid acutely.

SILENT syndrome (Syndrome of Irreversible Lithium-Effectuated NeuroToxicity):

Renal complications:

Endocrine:

Cardiac:

Hematologic: benign leukocytosis (don't anchor)

Dermatologic: acne, psoriasis exacerbation

Weight gain: significant in chronic use

Seizures: in acute severe toxicity, or lowered threshold in chronic users

Mortality:

Pregnancy/fetal outcomes: Ebstein anomaly, neonatal toxicity (above)

When to Escalate — ICU, Consults, Inpatient Triage

— Altered mental status (GCS <14) or progressive obtundation

— Seizures

— Hemodynamic instability (hypotension requiring pressors)

— Severe dysrhythmia or high-grade AV block

— Level >3.5 mEq/L regardless of symptoms (acute) or >2.5 mEq/L in chronic toxicity with neuro findings

— Need for hemodialysis

— Intubation for airway protection

— Level 2.0–3.5 with mild-moderate symptoms responding to IVF

— Need for serial lithium levels and neuro monitoring

— Stable but requires monitoring during clearance

— Mild symptoms, level <2.0, hemodynamically stable

— Reliable downward trend on fluids

— Cleared by psychiatry if intentional ingestion

— Toxicology / Poison Control (1-800-222-1222) — call early, document recommendation

— Nephrology — for any patient meeting HD criteria or borderline

— Psychiatry — all intentional ingestions; medical clearance before psych transfer

— Cardiology — for dysrhythmias or new conduction abnormalities

— OB/MFM — pregnant patients

— Asymptomatic, accidental single-dose ingestion <1.5 mEq/L

— Tolerating PO, no QT prolongation

— Reliable follow-up arranged with prescribing psychiatrist

— Outpatient level recheck in 24–48 hours

CCS pearl: For a CCS case with severe lithium toxicity at a community hospital, the correct sequence is: stabilize airway/IV access → start NS → call poison control → nephrology consult or transfer for HD → ICU admission. Document each step and the transfer rationale.

ICU admission criteria:

Step-down/telemetry admission:

Floor admission:

Consults:

Discharge from ED criteria (rare but possible):

Transfer considerations: If your facility lacks dialysis capability and patient meets HD criteria, transfer to tertiary center is mandatory — do not delay; arrange while initiating fluids and supportive care

Key Differentials — Same-Category (Toxicologic) Causes

— Triad: mental status change, autonomic instability, neuromuscular hyperactivity (clonus, hyperreflexia, especially lower extremities)

— Recent SSRI/SNRI, MAOI, tramadol, linezolid, methylene blue exposure

— Onset within hours of new agent or dose change

— Overlaps with lithium: many bipolar patients on both — can coexist

— Treatment: stop agent, benzodiazepines, cyproheptadine

— Lead-pipe rigidity, hyperthermia, altered mental status, autonomic instability, elevated CK

— Recent antipsychotic exposure (or rapid dopaminergic withdrawal in Parkinson's)

— Slower onset (days), bradyreflexia (vs hyperreflexia in serotonin syndrome)

— Treatment: stop antipsychotic, supportive care, dantrolene/bromocriptine

Board pearl: A bipolar patient on lithium + fluoxetine with hyperthermia, clonus, and AMS — lithium toxicity + serotonin syndrome coexist in this scenario. Check lithium level AND recognize the serotonergic syndrome. Stop both, supportive care, consider HD if level severe, cyproheptadine for serotonin syndrome.

Serotonin syndrome:

Neuroleptic malignant syndrome (NMS):

Anticholinergic toxicity: hyperthermia, dry skin, mydriasis, urinary retention, delirium — "mad as a hatter, dry as a bone"

Sympathomimetic toxicity (cocaine, meth, MDMA): hypertension, tachycardia, diaphoresis (sweating distinguishes from anticholinergic)

Salicylate toxicity: tinnitus, mixed respiratory alkalosis/anion gap metabolic acidosis, hyperthermia, AMS — also enhanced clearance with alkalinization or HD

Valproate toxicity: AMS, hyperammonemia, cerebral edema — treat with l-carnitine

TCA overdose: wide QRS, anticholinergic features, seizures, hypotension — sodium bicarbonate

Benzodiazepine or sedative overdose: respiratory depression, miosis, normal vitals otherwise

Carbamazepine or phenytoin toxicity: ataxia, nystagmus, dysarthria — mimic lithium cerebellar features closely

Methanol/ethylene glycol: AMS, severe anion gap acidosis, visual changes (methanol), oxalate crystals (EG)

Key Differentials — Other-Category Causes

— Acute focal cerebellar ataxia, dysarthria, nystagmus mimics lithium

— Distinguish: focal/unilateral findings, sudden onset, vascular risk factors

— CT/MRI head, NIHSS, neurology consult

— Meningitis, encephalitis — fever, headache, neck stiffness, AMS

— LP if no contraindication, empiric antibiotics + acyclovir if suspected

— Lithium toxicity can also cause low-grade fever and leukocytosis — don't anchor

— Hyponatremia (especially in chronic lithium patients with SIADH from comorbid conditions, or in DI patients given hypotonic fluids)

— Hypoglycemia — always check fingerstick

— Hyperammonemia (hepatic encephalopathy, valproate)

— Uremic encephalopathy in AKI/CKD

— Hyper- or hypocalcemia

— Catatonia (especially in bipolar/schizoaffective patients) — can mimic obtundation

— Conversion disorder — diagnosis of exclusion

Key distinction: Lithium toxicity has diffuse, symmetric neurologic findings (cerebellar + UMN + AMS). Focal deficits should redirect to stroke workup — get the CT head. Never assume neuro changes in a bipolar patient on lithium are "just" toxicity without basic alternative workup.

Stroke (cerebellar/brainstem):

CNS infection:

Metabolic encephalopathy:

Wernicke encephalopathy: confusion, ataxia, ophthalmoplegia — alcoholic, malnourished — empiric thiamine

Hypothyroidism / myxedema coma: relevant because chronic lithium causes hypothyroidism; check TSH

Seizure-related postictal state: known epilepsy, witnessed event, tongue bite, incontinence

Posterior reversible encephalopathy syndrome (PRES): severe hypertension, headache, vision changes, seizures

Psychiatric causes:

Other electrolyte/endocrine: thyroid storm, adrenal crisis, DKA, HHS

Sepsis with encephalopathy: especially in elderly — broad infectious workup parallel to lithium evaluation

Secondary Prevention, Discharge Medications, Long-Term Plan

— Severity of bipolar illness vs alternatives

— Reversibility of toxicity precipitant (e.g., self-limited illness vs new CKD)

— Patient preference and adherence capacity

— If restarting: lower dose, slower titration, more frequent monitoring

— Valproate: first-line alternative for bipolar maintenance, avoid in pregnancy (teratogenic)

— Lamotrigine: especially for bipolar depression maintenance; slow titration for Stevens-Johnson risk

— Quetiapine, lurasidone, olanzapine: second-generation antipsychotics with bipolar indications

— Carbamazepine: less commonly used due to interactions

— Recognize early toxicity signs: coarse tremor, GI symptoms, ataxia, confusion

— Maintain consistent fluid and salt intake — no crash diets, no extreme exercise without hydration

— Avoid NSAIDs (acetaminophen is safe alternative)

— Notify all prescribers of lithium before any new medication

— Hold lithium during gastroenteritis, fever, vomiting/diarrhea — call provider

— Carry medical alert ID

— Review every med with prescribing psychiatrist and PCP

— Flag interacting drugs in EMR

— Pharmacy consult for medication review in polypharmacy patients

— Avoid alcohol (worsens dehydration, lowers seizure threshold)

— Caffeine moderation (diuretic effect)

— Regular sleep (sleep deprivation triggers mania → relapse)

Step 3 management: After lithium toxicity, the outpatient discharge plan must include: PCP appointment within 1 week, psychiatry within 2 weeks, repeat BMP and lithium level in 5–7 days, and explicit written instructions about hydration, NSAID avoidance, and sick-day rules. Lithium-naïve restart should be considered carefully — sometimes alternative agents are safer long-term.

Decision to restart lithium after toxicity:

Alternative mood stabilizers if lithium unsafe:

Patient education at discharge (mandatory documentation):

Coordinate medication reconciliation:

Lifestyle:

Follow-Up, Monitoring Parameters, and Counseling

— Lithium level: every 3–6 months when stable; sooner with dose changes, new meds, or illness

— BMP (creatinine, electrolytes): every 6–12 months, including eGFR trending

— TSH: every 6–12 months (free T4 if abnormal)

— Calcium: annually (hyperparathyroidism risk)

— CBC: annually

— ECG: baseline and as clinically indicated; consider in patients >50 or with cardiac risk

— Urinalysis and urine osmolality: if polyuria/polydipsia suspected (DI screen)

— Dose change → recheck level in 5–7 days (steady state achieved by then)

— New interacting medication → check level in 1 week

— Acute illness → hold or reduce dose, recheck when recovered

— New CKD diagnosis → more frequent monitoring, consider switching agent

— 12-hour trough — drawn 12 hours after last dose, before morning dose

— Mistimed levels misinform decisions

— Annual eGFR; consider nephrology referral if eGFR falls >25% or <60 sustained

— Mood monitoring, sleep, side effect screen

— Annual depression/suicide risk assessment

— Family/caregiver involvement in monitoring

— Pregnancy planning — discuss before conception, switch if appropriate

— Contraception in reproductive-age women

— Vaccinations, especially flu (illness triggers toxicity)

— Mental health crisis resources

Board pearl: Annual eGFR, TSH, and calcium are the three labs the boards expect you to monitor in chronic lithium users beyond the level itself. Forgetting calcium misses lithium-induced hyperparathyroidism, which can present years into therapy with nephrolithiasis or osteoporosis.

Routine outpatient lithium monitoring (the Step 3 favorite):

Frequency intensification triggers:

Timing of lithium level:

Long-term renal monitoring:

Bipolar disorder follow-up:

Counseling topics:

Ethical, Legal, and Patient Safety Considerations

— Lithium toxicity itself impairs cognition — capacity decisions may need delay until medically cleared

— If patient refuses care during acute toxicity, emergency exception to consent applies for life-threatening treatment

— Document mental status serially; reassess capacity as toxicity resolves

— Intentional overdose → involuntary psychiatric hold (state-specific: 5150 in CA, Section 12 in MA, etc.)

— Medical clearance required before psych transfer — do NOT transfer with uncorrected toxicity

— Document suicide risk assessment, safety plan, means restriction counseling

— Suspected child or elder abuse if pediatric/elderly ingestion suggests neglect or intentional harm

— Suicide attempt documentation per institutional policy

— Lithium toxicity often occurs at medication transitions: hospital discharge with new ACEi for HTN, primary care starting NSAID without psychiatry knowledge, urgent care prescribing diuretic

— Closed-loop communication between psychiatry, PCP, and any new prescriber is mandatory

— Use of pharmacy interaction alerts and EMR flags

— Verify med reconciliation at every transition

— Emergency HD does not require formal consent if patient lacks capacity and HD is life-saving (implied consent)

— When time permits, consent from patient or surrogate documented

— After significant toxicity, persistent neurologic deficits may impair driving — counsel and document

— Occupational considerations for jobs requiring fine motor or cognitive precision

— Discuss teratogenic risk with women of reproductive age starting lithium; document the conversation

— Provide contraception counseling

— Adverse drug events from preventable interactions should be reported through institutional safety systems for systems-level prevention

Step 3 management: A patient discharged after lithium toxicity precipitated by a new thiazide started at a different practice — file a patient safety event report, document medication reconciliation failure, and arrange a shared care plan between psychiatry and primary care. This is a classic transition-of-care error.

Capacity assessment in intentional overdose:

Psychiatric hold:

Mandatory reporting:

Transition-of-care risks (high-yield Step 3 area):

Informed consent for hemodialysis:

Driving and occupational safety:

Pregnancy disclosure:

Patient safety event reporting:

High-Yield Associations and Rapid-Fire Clinical Facts

Board pearl: When a question stem mentions a bipolar patient with a new ACE inhibitor, NSAID, or thiazide plus tremor/ataxia/confusion — the answer is almost always lithium toxicity. Check the level, stop the offender, hydrate.

Lithium therapeutic range: 0.6–1.2 mEq/L maintenance; toxicity >1.5

Lithium is renally excreted unchanged — no hepatic metabolism

Drugs that raise lithium levels: thiazides, ACEi, ARBs, NSAIDs, metronidazole, tetracyclines

Drugs that lower lithium levels: caffeine, theophylline, acetazolamide, osmotic diuretics

Activated charcoal does NOT bind lithium

Sodium polystyrene sulfonate binds lithium but causes hypokalemia — not standard

Whole-bowel irrigation for sustained-release ingestions

Hemodialysis is treatment of choice for severe toxicity

Rebound rise post-HD from tissue redistribution — recheck level 6–8h after session

Nephrogenic DI: lithium reduces collecting duct AQP2 — treat with amiloride

Hypothyroidism: 20% of chronic users; check TSH every 6–12 months

Hyperparathyroidism with hypercalcemia: 10% of chronic users

Pregnancy: small Ebstein anomaly risk; fetal echo at 16–20 weeks if exposed

Floppy baby syndrome: neonatal lithium toxicity (cyanosis, hypotonia, transient)

SILENT syndrome: persistent cerebellar/cognitive deficits after toxicity

Coarse tremor: toxicity sign (fine tremor is baseline therapeutic effect)

Acute toxicity: GI symptoms early, neuro late

Chronic toxicity: neuro dominant, GI mild — worse prognosis at lower levels

ECG: T-wave flattening/inversion, QT prolongation, sinus node dysfunction

Benign leukocytosis with lithium — don't pursue infection workup based on WBC alone

Lithium-heparin tube falsely elevates lithium level — use plain tube

Volume of distribution: ~0.7 L/kg (small) — why HD works so well

Lithium decreases suicidality more than any other psychotropic — reason to restart when safe

Halophilia of lithium: behaves similarly to sodium at renal tubule

Board Question Stem Patterns

"A 68-year-old woman with bipolar disorder on lithium for 20 years presents with new-onset coarse tremor, ataxia, and confusion. She was recently started on lisinopril for hypertension. Level is 1.8 mEq/L." → Diagnosis: chronic lithium toxicity. Stop lisinopril, hold lithium, IVF, monitor; consider HD if neuro worsens.

"A 24-year-old man with bipolar disorder is brought to the ED 2 hours after ingesting "a whole bottle" of his lithium. He has nausea and vomiting but is alert. Level is 3.2 mEq/L." → Acute toxicity. NS resuscitation, serial levels q2h (sustained-release may peak late), whole-bowel irrigation if SR formulation, ICU admission, prepare for HD if level rises >4 or symptoms develop.

"A 55-year-old on chronic lithium found obtunded at home, seizing. Level 4.5 mEq/L, Cr 2.8." → Emergent hemodialysis, ICU, intubate, IVF, treat seizures with benzodiazepines.

"Patient on lithium with polyuria 5 L/day, serum Na 148, urine osm 120, no response to desmopressin." → Lithium-induced nephrogenic DI. Treat with amiloride; consider switching mood stabilizer.

"Bipolar patient on lithium 5 years presents with fatigue, weight gain, cold intolerance. TSH 18." → Lithium-induced hypothyroidism. Start levothyroxine; continue lithium.

"Pregnant patient at 8 weeks on lithium; concerned about teratogenicity." → Discuss small Ebstein anomaly risk; fetal echo at 16–20 weeks; do NOT abruptly stop lithium without psychiatric consultation.

"Patient on stable lithium develops worsening arthritis; PCP starts ibuprofen." → NSAIDs raise lithium levels; recommend acetaminophen instead.

"Patient on lithium with bradycardia and T-wave inversions." → Lithium effect on ECG; benign unless symptomatic or new conduction abnormality.

"Which patient needs HD?" → Look for level >4, neuro features, renal impairment, or hemodynamic instability.

Key distinction: Acute ingestions emphasize decontamination and serial levels (kinetic problem). Chronic toxicity emphasizes identifying the precipitant and supportive care/HD (clinical severity problem). The exam tests whether you choose management based on the right axis.

Pattern 1 — Chronic toxicity from new medication:

Pattern 2 — Acute intentional overdose:

Pattern 3 — Acute-on-chronic with severe features:

Pattern 4 — Nephrogenic DI:

Pattern 5 — Hypothyroidism in chronic user:

Pattern 6 — Pregnancy considerations:

Pattern 7 — Drug interaction trap:

Pattern 8 — ECG findings:

Pattern 9 — HD indication question:

One-Line Recap

Lithium toxicity is a renally-mediated, dose-and-context-dependent emergency where acute ingestions cause early GI then late neuro symptoms, chronic toxicity causes predominantly neurologic disease at deceptively modest serum levels driven by dehydration or interacting drugs (NSAIDs/ACEi/thiazides), and management hinges on aggressive isotonic saline, removal of precipitants, and hemodialysis for severe neurologic features or levels >4 (acute) / >2.5 (chronic with symptoms).

Rapid-fire high-yield recaps:

Board pearl: When in doubt on the exam, the lithium toxicity answer almost always involves either identifying a drug interaction (ACEi/NSAID/thiazide), starting normal saline, or initiating hemodialysis — and the patient's clinical severity, not just the serum level, drives the decision.

Diagnose smart: serial lithium levels (q2h, plain tube), BMP, ECG, TSH, calcium, pregnancy test; remember sustained-release peaks 6–12h late and chronic toxicity is worse than the number suggests.

Treat fast: 0.9% NaCl 150–300 mL/h, stop offending drugs (NSAIDs, ACEi/ARBs, thiazides), benzodiazepines for seizures, no activated charcoal, whole-bowel irrigation only for SR ingestion, and call nephrology for HD in severe cases — expect rebound levels 6–8 h post-dialysis.

Long-term win: monitor level every 3–6 months, BMP/TSH/calcium annually, screen for nephrogenic DI (treat with amiloride) and hypothyroidism (treat with levothyroxine), educate on hydration/sick-day rules/NSAID avoidance, and coordinate transitions of care to prevent the next toxicity event.

Special populations: elderly need lower targets (0.4–0.8), pregnancy requires dose adjustments around delivery and fetal echo screening, and CKD eGFR <30 generally contraindicates lithium — switch to valproate or lamotrigine.